Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

2012200 citationsJournal Articlebronze Open Access

Authors

Akira Honda · Tokyo Medical University Ibaraki Medical Center

Tadashi Ikegami · Tokyo Medical University Ibaraki Medical Center

Makoto Nakamuta · National Kyushu Medical Center

Teruo Miyazaki · Tokyo Medical University Ibaraki Medical Center

Junichi Iwamoto · Tokyo Medical University Ibaraki Medical Center

Takeshi Hirayama · Tokyo Medical University Ibaraki Medical Center

Abstract

Bezafibrate is a dual PPARs/PXR agonist with potent anticholestatic efficacy in early-stage PBC patients with an incomplete biochemical response to UDCA monotherapy.

Topics & Keywords

Liver Disease Diagnosis and Treatment Drug Transport and Resistance Mechanisms Liver Diseases and Immunity

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology

Volume 57, Issue 5, pp. 1931-1941

DOI: 10.1002/hep.26018

Field-Weighted Citation Impact: 11.50